文献速递哮喘

Tezepelumab在真实世界美国重症哮喘患者中的4期PASSAGE研究

Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

PASSAGE是一项4期、多中心、单臂、开放标签、为期12个月的研究,纳入286例重症未控制哮喘患者,覆盖不同表型和代表性不足人群。结果显示,tezepelumab治疗期间年化哮喘急性发作率较基线下降70%(95%CI 63%-75%),各表型和代表性不足人群下降54%至77%,且未发现新的安全性信号。

要点

  • Tezepelumab使重症哮喘年化急性发作率从2.88降至0.87,下降70%。
  • 各表型及代表性不足人群发作率下降54%至77%。
  • 第52周整体FEV1较基线增加0.122 L,未发现新安全性信号。

核心结论

  • 在真实世界美国重症未控制哮喘人群中,tezepelumab显著减少急性发作并改善肺功能、哮喘控制和生活质量。

研究设计与样本

  • PASSAGE为4期、多中心、单臂、开放标签、12个月研究,纳入286例≥12岁重症未控制哮喘患者。
  • 研究覆盖不同表型(血嗜酸性粒细胞≥300或<300 cells/µL,伴或不伴过敏)及代表性不足人群。

主要发现

  • 年化哮喘急性发作率从基线2.88降至治疗期0.87,下降70%(95%CI 63%-75%)。
  • 各表型和代表性不足人群的年化哮喘急性发作率下降54%至77%。
  • 第52周整体FEV1较基线增加0.122 L(95%CI 0.07-0.17)。
  • 基线FEV1占预计值≤80%者第52周FEV1较基线增加0.212 L(95%CI 0.15-0.28)。
  • 第52周51%至91%的患者在ACQ-6、AIRQ和SGRQ上出现有临床意义的改善。

临床怎么用

  • 对于重症未控制哮喘患者,可考虑使用tezepelumab以减少急性发作并改善肺功能和控制水平。
  • 不同血嗜酸性粒细胞水平、过敏状态及代表性不足人群均可从tezepelumab治疗中获益。

局限性

  • 研究为单臂、开放标签设计,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Clinical trials of severe asthma therapies often exclude or underrepresent key patient populations. OBJECTIVES: To evaluate the effectiveness and safety of tezepelumab in a diverse, real-world US population with severe, uncontrolled asthma (SUA). METHODS: PASSAGE was a phase 4, multicenter, single-arm, open-label, 12-month study enrolling patients with SUA (≥12 years old), including different phenotypes (blood eosinophil count ≥300 or <300 cells/µL, with or without allergy) and underrepresented populations (Black/African American patients, adolescents, those with SUA with comorbid mild-to-moderate chronic obstructive pulmonary disease, people with a significant smoking history [≥10 pack-years]). The primary outcome was the annualized asthma exacerbation rate (AAER) in the 12 months before (baseline period) and after (treatment period) tezepelumab initiation. MEASUREMENTS AND MAIN RESULTS: Among 286 participants, AAER decreased by 70% (95% CI, 63%-75%) from 2.88 (baseline period) to 0.87 (treatment period) and by 54% to 77% across phenotypes and underrepresented populations. At week 52, least-squares mean pre-bronchodilator FEV1 increased from baseline by 0.122 L (95% CI, 0.07-0.17) overall and by 0.212 L (95% CI, 0.15-0.28) among participants with percent predicted pre-bronchodilator FEV1 ≤80% at baseline. Clinically meaningful improvements in Asthma Control Questionnaire-6, Asthma Impairment and Risk Questionnaire, and St George's Respiratory Questionnaire scores were observed in 51% to 91% of participants across phenotypes and underrepresented populations at week 52. No new safety signals were identified. CONCLUSIONS: The PASSAGE study of a diverse, real-world US population with SUA treated with tezepelumab demonstrated substantial reductions in asthma exacerbations across phenotypes and underrepresented populations as well as clinically meaningful improvements in lung function, asthma control, and health-related quality of life. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov (NCT05329194).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Lugogo, Akuthota, Sumino, et al. Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study. Am J Respir Crit Care Med. 2026. PMID: 42148905. doi:10.1093/ajrccm/aamag225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。